

Corporate Presentation



September 3, 2026

VAXCYTE
protect humankind™

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s carrier-sparing platform and vaccine candidates, including breadth of coverage and the ability to deliver potentially better immune responses, best-in-class vaccines and the improvement upon the standard-of-care; demand for Vaxcyte’s vaccine candidates; the design, timing of initiation, progress and expected results of Vaxcyte’s preclinical studies, clinical trials and research and development plans; the ability of Vaxcyte’s cell-free platform to deliver the broadest-spectrum PCVs that provide protection against both currently circulating and historically prevalent strains; applicability of precedent criteria for licensure; Vaxcyte’s ability to establish global commercial manufacturing capacity for its PCV candidates; the ability of Vaxcyte to commercialize its PCV candidates and to meet the PCV franchise market demand for commercial markets; the use and availability of funds from NIH; the growth and expansion of the pneumococcal vaccine market, and the potential to address the need for broader-spectrum of coverage in such market; the market opportunity for Vaxcyte’s vaccines; Vaxcyte’s expectations regarding the potential benefits, spectrum coverage, clinical or regulatory pathways, adoption speed and immunogenicity of its vaccine candidates and other statements that are not historical fact. The words “anticipate,” “believe,” “continue,” “could,” “designed,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities; potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates; the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

A background image of a male scientist in a white lab coat and safety glasses, looking down at a piece of laboratory equipment. The image is slightly blurred and has a dark overlay to make the text stand out.

VAXCYTE MISSION STATEMENT

We are on a global mission to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases.

Highlights: Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Enrollment Completed in VAX-31 OPUS-1 Phase 3, Noninferiority Trial Designed to Establish Fulsome Coverage for Adults

POTENTIAL BEST-IN-CLASS PCV FRANCHISE

- **Carrier-sparing, site-specific conjugation platform** enabling broader-spectrum PCVs
- **Adult Indication:**
 - **VAX-31:** Broadest-spectrum PCV in the clinic
 - Enrollment completed in OPUS-1, OPUS-2 and OPUS-3 Phase 3 trials
 - FDA BTB granted for IPD and pneumonia
 - Designed to cover 95% of IPD while maintaining pressure on currently circulating and historically disease-causing serotypes in U.S. adults ≥ 50 years of age
- **Pediatric Indication:**
 - **VAX-24:** Announced final data from positive infant Phase 2 dose-finding study
 - **VAX-31:** Enrollment completed in Phase 2 dose-finding study, which includes multiple higher doses designed to optimize immune responses in children
- **VAX-XL: Third-generation PCV to further expand coverage**

HIGHLY ATTRACTIVE PCV MARKET

- **Well-defined ~\$8B market segment poised for substantial growth**
 - **Age range in U.S. recently expanded to include adults ≥ 50 years of age;** and
 - Many developed countries now adopting **universal vaccination of older adults**
- Leverages established surrogate immune endpoints as basis for full approval, **negating need for field efficacy studies to support licensure**
- Serotype and disease spectrum of coverage is the **primary adoption driver**, yet incumbents **limited to partial coverage, which is driven by carrier suppression**

EXCLUSIVE CELL-FREE PLATFORM


- **Vaxcyte PCV Franchise**
 - Leverages **site-specific conjugation** to expose protective T-cell antigens
 - Enables **carrier-sparing** conjugates that honor well-understood PCV MOA
- Permits production of **“tough-to-make” antigens**
- **Platform unlocks large market opportunities beyond PCVs**, including Group A Strep and Shigella
- **VAX-A1:** Novel Group A Strep vaccine
 - Phase 1 study in adults underway
- **VAX-GI:** Novel Shigella vaccine

ALIGNED CRITICAL RESOURCES

- **Strategic Manufacturing Approach**
 - Building out capacity to satisfy global PCV demand for developed markets
 - Global commercial manufacturing agreement with Lonza to produce key PCV components
 - Agreement with Thermo Fisher Scientific to establish U.S. fill-finish manufacturing; expands domestic capacity to support future commercial manufacturing
- **Seasoned management team**, directors and advisors
- **~\$2.5 billion in cash, cash equivalents and investments** as of 6/30/26

Cell-Free Protein Synthesis Platform Unlocks Multiple Vaccine Applications

Facilitates Design and Production of Proteins Beyond the Reach of Conventional Methods



SPEED, FLEXIBILITY, SCALABILITY

- Rapidly screen vaccine candidates
- Flexible reaction conditions
- Large-scale production achieved using standard equipment

SUPERIOR CONJUGATE VACCINES


- Site-specifically attach antigens onto protein carriers designed to:
 - Enable consistent exposure of T-cell epitopes and/or B-cell epitopes on protein carrier
 - Avoid off-target effects
 - Enable use of less protein carrier without sacrificing immunogenicity
 - Enable broader-spectrum vaccines

NOVEL PROTEIN VACCINES

- Able to produce “tough-to-make” protein antigens that conform to target pathogens
- Increased likelihood of protective immune response

Pipeline of High-Fidelity Vaccines with Multiple Near-Term Milestones

Broad-Spectrum Conjugate and Novel Protein Vaccines to Prevent Bacterial Infectious Diseases



Anticipated 2026 and 2027 Key Milestones

VAX-31 ADULT INDICATION

- Announce safety, tolerability and immunogenicity data from the:
 - OPUS-1** Phase 3 pivotal, noninferiority trial by the end of October 2026 (topline data)¹
 - OPUS-2** and **OPUS-3**² trials in the first half of 2027³

VAX-31 INFANT INDICATION³

- Announce topline data from the ongoing Phase 2 dose-finding study from both the primary three-dose immunization series and booster dose either sequentially or together by the end of the first half of 2027

VAX-A1³

- Announce topline data from the Phase 1, first-in-human adult study⁴ in the second half of 2027

(1) Guidance as of September 3, 2026.

(2) OPUS-2 is a Phase 3 trial evaluating concomitant administration of VAX-31 with a seasonal influenza vaccine; OPUS-3 is a Phase 3 trial evaluating VAX-31 in adults who have previously received pneumococcal vaccination.

(3) Guidance as of August 5, 2026.

(4) VAX-A1 Phase 1, first-in-human study has the primary objective of evaluating safety and tolerability and is being conducted in Australia.

Experienced Management Team with Track Record in Vaccines and Biopharma

Grant Pickering, MBA

*Chief Executive Officer,
Director & Co-Founder*



Andrew Guggenhime, MBA

*President
& Chief Financial Officer*



Jim Wassil, MS, MBA

*Executive VP, Chief Operating Officer
& Chief Scientific Officer*



Mike Mullette, MBA

Chief Commercial Officer



Luis Jodar, PhD

Chief Medical Officer



Chris Griffith, MS, MBA

Chief Business & Strategy Officer



Harp Dhaliwal, MBA

Chief Technical Operations Officer



Jeff Fairman, PhD

VP Research & Co-Founder



PCV Opportunity

VAXCYTE
protect humankind™



Global Health Impact of Pneumococcal Disease Remains Significant



ABOUT STREPTOCOCCUS PNEUMONIAE

Streptococcus pneumoniae is the most common pathogen causing pneumococcal disease (PD)

- Non-invasive PD includes otitis media, sinusitis, pneumonia
- Invasive PD (IPD) includes bacteremia, meningitis
- Pneumococci cause over 50% of bacterial meningitis cases in the U.S.



CURRENT ~\$8 BILLION GLOBAL VACCINE CATEGORY

Vaccinations are recommended globally for infants and adults to prevent PD^{1,2}

- >170 countries have officially introduced PCVs into national immunization programs³
- Routine SoC schedule in the U.S.:
 - Infants:
 - Prevnar 20® (PCV20) x 4 doses; or
 - Vaxneuvance® (PCV15) x 4 doses
 - Adults aged 50 and older (single dose):
 - PCV20 or Capvaxive™ (PCV21); or
 - PCV15 & Pneumovax® 23 (PPV23)



GLOBAL INCIDENCE & IMPACT OF PD STILL SUBSTANTIAL


Global pneumococcal disease in children is driven by emerging serotypes not covered by currently available vaccines and in adults by not only emerging serotypes, but also fragmented coverage of today's standard of care vaccines

- *Streptococcus pneumoniae* is the leading cause of vaccine-preventable deaths globally in children under five⁴
- ~225K U.S. adult hospitalizations annually caused by pneumococcal pneumonia⁵
- ~300K children under five years old die annually worldwide due to *Streptococcus pneumoniae*⁶

Serotype Replacement Drives Need for Broader-Spectrum Vaccines

Non-Vaccine Serotypes Increase in Prevalence, as Circulation of Vaccine Serotypes is Eliminated, Resulting in the Need for Broader-Spectrum Vaccines

UK IPD CASES IN ADULTS ≥ 65 ¹




Limitations of Current PCVs

Coverage Expansion Needed to Address Circulating Disease, but Protein Carrier Backbone Problematic

LIMITATIONS OF CONVENTIONAL CHEMISTRY

- Random conjugation masks on-target T-cell epitopes on the protein carrier
- Conventional reductive amination chemistry requires higher amounts of protein carrier than polysaccharide to form stable conjugates
- Overabundance of protein carrier exacerbates carrier suppression, due to competition for CD4+ help between disease-specific polysaccharides and non-disease specific protein carrier

PROTEIN CARRIER DIVERTS IMMUNE RESPONSE



Limitations of Current PCVs: Adding Conjugates Results in Lower Ab Titers


Coverage Expansion Using Conventional Chemistry Has Led to Carrier-Induced Immune Suppression

CARRIER SUPPRESSION


Diminished immune response to target polysaccharides due to cumulative amount of protein carrier

- Expanded spectrum of coverage requires increasing protein carrier burden
- Reduced immune responses consistently demonstrated with > spectrum PCVs in both infants and adults

**INFANT IMMUNE RESPONSES (IgG):
PCV20 VS PCV13¹**



**ADULT IMMUNE RESPONSES (OPA):
PCV20 VS PCV13²**



(1) Immunoglobulin G (IgG) Geometric Mean Concentrations post-dose 4 – Prevnar 20 BLA Clinical Review Memorandum by FDA (STN: 125731/189). April 27, 2023.


(2) Prevnar 20 BLA Clinical Review Memorandum. STN: 125731/0 June 8, 2021.

OPA = opsonophagocytic activity; GMR = geometric mean ratio.

Vaxcyte's PCV Franchise Employs Carrier-Sparing Conjugates

Cell-Free Platform Enables Precise Conjugation to Enhance Potency of Standard Protein Carrier


PROPRIETARY eCRM[®] PROTEIN CARRIER WITH PRECISE, SITE-SPECIFIC CONJUGATION SITES



eCRM: Enhanced Potency Potential

- Avoids masking sites on CRM₁₉₇ carrier responsible for T-cell help
- Optimized sites for conjugation using copper-free click chemistry
- More consistent antigenic presentation

VAXCYTE CARRIER-SPARING CONJUGATES MIMIC THE CUSTOMARY MATRIX FORM



Carrier-Sparing Conjugates

- Less protein carrier / conjugate may allow addition of more serotypes while minimizing carrier suppression and maintaining immunogenicity
- VAX-31 and VAX-24 conjugates form standard PCV interstrand crosslinked matrices
 - Perceived as foreign by the host
 - Allows use of standard critical quality attributes and serological assays

Vaxcyte PCV Franchise Design Leverages Many Standard PCV Conventions

Utilizes Proven Components, Chemistries and Assays to Reduce Risk and Uncertainty

	Polysaccharide		Protein Carrier			Assays	
	CDAP / Periodate Activation	Amination for Labeling PS	Incorporation of Non-natural AAs	Random Lysine Conjugation	Site-Specific Click Chemistry Conjugation	CQA Release Assays (Mol Wt, Free PS)	Serological Assays (IgG & OPA)
Pfizer/Merck Methods	✓	✓		✓		✓	✓
Vaxcyte	✓	✓	✓		✓	✓	✓


Novel Enablement: Site-specific conjugation via incorporation of nnAA conjugation anchors

Vaxcyte's PCV Franchise Has More Fulsome Coverage Versus On-Market PCVs

Pneumococcal Vaccines Represent One of the Largest Segments of Global Vaccine Market, with Significant Growth Expected¹

VAX-31: 31-valent PCV, the broadest-spectrum PCV in the clinic, designed to cover both currently circulating and long-established, historically disease-causing serotypes

VAX-24: 24-valent PCV designed to cover more serotypes than any pediatric pneumococcal vaccine on-market today



SoC = standard of care. Source: Prescribing information for Prevnar, Prevnar 13, Prevnar20, Synflorix, Vaxneuvance, Prevnar 20 and Capvaxive. Company filings for Vaxcyte. Capvaxive is approved for use in adults only.

(1) Public Company Reports: PFE, MRK, SNY, MRNA, GSK, AZN, excluding Covid-19 vaccine sales.

(2) The serogroup 20 antigen contained in VAX-24 and VAX-31, formerly known as a 20B variant, has been officially reclassified as 20C. Due to the significant structural homology between 20C and 20B, immune responses elicited by 20C have been demonstrated to be highly cross-reactive with 20B. The Company therefore expects to be able to demonstrate coverage for both serotypes, 20B and 20C, in the VAX-31 adult Phase 3 and infant Phase 2 studies. Reference: Yu J, et al.; New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B. Microbiol Spectr 0:e02443-24. Within the serotype 20 group, strain 20B is the predominant circulating strain and shows greater genetic similarity to 20C compared to 20A. PCV21 includes 20A, VAX-31 includes 20C, with 20B planned to be evaluated in clinical studies to demonstrate cross protection.

Pneumococcal Vaccine Market is Highly Attractive

Vaxcyte's PCV Franchise Has the Potential to Be Best-in-Class Due to Broader Coverage and Improved Immunogenicity

PNEUMOCOCCAL VACCINE MARKET DYNAMICS

PCVs ARE HIGHLY EFFECTIVE

- Well-understood T-cell dependent MOA tied to co-presentation of disease-specific polysaccharide antigens with T-cell epitopes on protein carrier to drive durable and boostable immune responses
- Well-defined clinical development path with surrogate immune endpoints as basis for full approval, negating need for field efficacy trials

DURABLE & RAPID REVENUE

- Prevnar Family (PCV7/PCV13/PCV20) & PPSV23 have generated >\$100B in revenues
- PCV13 and PCV20 had combined annual sales of ~\$6.5B in 2025
- PCV21 generated \$759M in 2025 (launched 3Q 2024)


ATTRACTIVE MARGINS

- Pneumococcal vaccines are premium priced, delivering highly attractive margins
- Broader-spectrum PCVs extend premium price in the U.S.¹
 - PCV21: \$302 (adult)
 - PCV20: \$299
 - PCV15: \$241 (pediatric)

COVERAGE & RECOMMENDING BODIES DRIVE ADOPTION

- Potential for rapid adoption, with spectrum of coverage and ACIP recommendation driving uptake
- Examples:
 - Shingrix® vs Zostavax®
 - Gardasil® vs Cervarix®
 - PCV20 vs PCV15

SEROTYPE & DISEASE COVERAGE ADVANTAGE IS PRIMARY DRIVER OF U.S. PCV MARKET ADOPTION




PCV VACCINATION IN ADULTS AGED ≥ 65
JULY 2021 - NOVEMBER 2023²

- Broader-spectrum of serotype and disease coverage drove 98% adoption for PCV20 over PCV15 despite ACIP recommendation of both vaccines

Pneumococcal Vaccine Market Poised for Significant Growth

Combined \$8B Market Expected to Grow to ~\$12B in 2030¹, Driven Primarily by Adult Market Expansion



Recent Burst of Adult PCV Recommendations Outside the U.S.

Serotype Epidemiology, Broad-Valency PCVs Driving New Recommendations and Shift from PPSV23 to PCVs

Licensure of broader-spectrum PCVs is driving adult universal recommendations internationally

Expanded Global Adult PCV Adoption

Japan

Switzerland

France

Spain (Regional)

Germany

United Kingdom

Netherlands

PCVs NOW RECOMMENDED¹

PRIOR ADULT RECOMMENDATION:


No Prior Universal, Age-Based PCV Recommendation or PPSV23 Only

International revenues for the Prevnar vaccine family increased ~8% year-over-year²

Commercial Strategy for U.S. Adult PCV Market

Initial Focus on Retail Pharmacies and Large Health Systems

~50% of U.S. Adult PCV Volume is Concentrated in 50-60 Accounts¹



RETAIL PHARMACIES¹

~45%

6 retail chains account for ~70-80% of adult PCV volume in pharmacies



IDNs / HEALTH SYSTEMS¹

~35%

~50 large health systems account for ~40-50% of adult PCV volume in segment



PHYSICIAN OFFICES¹

~20%

Physician offices represent an incremental growth opportunity for adult PCV volume

Establishing Manufacturing Capacity, Robust Supply Chain to Support Expected VAX-31 Adult U.S. Launch, Followed by U.S. Infant and Global Adult and Infant PCV Launches

Global Commercial Manufacturing Agreement with Lonza



- Relationship encompasses production of key PCV components
- Dedicated large-scale facility built to provide capacity for U.S. and global demand for adults and infants

U.S. Fill-Finish Manufacturing Agreement with Thermo Fisher




- Agreement expands domestic capacity (North Carolina)
- Supports future commercial manufacturing and deepens investment in American innovation and infrastructure

VAX-31 Adult Clinical Program



VAX-31 Designed to Expand Protection with Broadest Disease Coverage in Adults


Percentage of IPD and Non-Bacteremic Pneumococcal Pneumonia Covered by PCVs in U.S. Adults



All estimates assume cross-protection between serotypes 6A and 6C and between 15B and 15C.
(1) CDC 2022-2024 Active Bacterial Core (ABC) Surveillance data (https://data.cdc.gov/Public-Health-Surveillance/1998-2024-Serotype-Data-for-Invasive-Pneumococcal-/qvzb-qs6p/about_data); IPD cases with missing serotype data were excluded, non-typeable cases were included in the denominator.
(2) King LM et al. Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines, *The Journal of Infectious Diseases*, 2025, jiaf376; <https://doi.org/10.1093/infdis/jiaf376>; the percentage covered by PCV is based on a weighted average based on inpatient pneumonia cases (50–64 years of age, ≥65 years of age).

VAX-31 is Designed to Provide Comprehensive Coverage, While Maintaining or Improving Immune Response, Relative to Today's SoC that Only Provides Partial Coverage

Next Generation PCV Designed to Cover 95% of IPD and ~88% of Pneumococcal Pneumonia in U.S. Adults Aged 50+ with Potential to Provide an Incremental 13-36% Broader IPD Coverage and 19-31% Broader Pneumonia Coverage than Standard-of-Care Vaccines




SoC = standard of care.
(1) % of IPD caused in individuals ≥50 yrs of age in the U.S. in 2022-2024 based on ABC surveillance data.
(2) Serotypes 6A/6C and 15B/15C are closely related subtypes for which cross-protection is assumed. All three—PCV21, PCV20, and VAX-31—include 6A. PCV20 and VAX-31 include the 15B antigen; PCV21 contains the 15C antigen and demonstrated cross-reactive responses against serotype 15B, supporting an indication for IPD caused by 15B and 15C.
(3) Serotype 20 comprises closely related subtypes for which cross-protection is assumed. Within the serotype 20 group, strain 20B is the predominant circulating strain and shows greater genetic similarity to 20C compared to 20A. PCV21 includes 20A, VAX-31 includes 20C, with 20B planned to be evaluated in clinical studies to demonstrate cross protection. The serogroup contained in VAX-24 and VAX-31, formerly known as a 20B variant, has been officially reclassified as 20C. For additional details on serogroup 20, please see footnote 2 on slide 15.

VAX-31 Adult Phase 3 Program

VAX-31 OPUS Phase 3 Adult Program Overview (Subject Enrollment: n=6,191)


OPUS Clinical Program Designed to Support Potential BLA Filing; Enrollment Completed in OPUS-1, OPUS-2, and OPUS-3 Trials



BLA = Biologics License Application.
(1) Also planning for a manufacturing consistency study (e.g., a lot-to-lot study).
(2) Includes safety, tolerability and immunogenicity data.
(3) Guidance as of September 3, 2026.
(4) No known prior history of IPD or pneumococcal pneumonia, or receipt of any licensed or investigational pneumococcal vaccine.
(5) Guidance as of August 5, 2026.



OPUS-1 Phase 3 Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults (n=4,049 Dosed)

Study Designed to Establish New Standard for Adult PCVs Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31¹ with PCV21 and PCV20, the Current Standards of Care in U.S. Adults



OPUS-1 Phase 3 Pivotal Noninferiority Trial Key Objectives


Expected to Serve as Cornerstone of BLA Package for Potential Licensure in Adults

VAX-31 IMMUNOGENICITY STUDY OBJECTIVES		EVALUATION CRITERIA	
PRIMARY OBJECTIVES	Noninferiority compared with PCV21 and/or PCV20 for the 28 serotypes (STs) shared with either or both comparator vaccines in adults 50+	 OPA GMR LOWER BOUND OF TWO-SIDED 95% CONFIDENCE INTERVAL	>0.667
	Superiority of VAX-31 compared with PCV21 or PCV20 for the 3 STs unique to VAX-31 (2, 7C and 20C) and for ST 20B in adults 50+		>2.0
	Noninferiority of immune responses in adults aged 18-49 years compared with those in adults aged 50-64 years		>0.667
SECONDARY OBJECTIVES	Noninferiority compared with both PCV21 and PCV20 for the 11 STs common to all three vaccines in adults 50+	 OPA GMR LOWER BOUND OF TWO-SIDED 95% CONFIDENCE INTERVAL	>0.5
	Statistically greater immune responses relative to PCV21 or PCV20 for the 28 shared STs in adults 50+		>1.0
	Superiority compared with PCV20 for the 8 STs common to VAX-31 and PCV21 but not included in PCV20 in adults 50+		>2.0
	Superiority compared with PCV21 for the 9 STs common to VAX-31 and PCV20 but not included in PCV21 in adults 50+		>2.0
KEY SAFETY & TOLERABILITY OBJECTIVES			
Safety and tolerability will be evaluated for 6 months following initial vaccination, including SAE, NOCI, and MAAE; Day 1 to Day 7, solicited local reactions and solicited systemic events will be evaluated; Day 1 to Month 1, all unsolicited AEs will be evaluated			


OPA GMR Responses for VAX-31 (Phase 2) and PCV21 (Phase 3) vs PCV20

VAX-31 GMRs Higher on 18 of 20 Common STs and 7 STs Achieved Statistically Higher Immune Responses¹

VAX-31 HIGH DOSE PHASE 2 NI STUDY VS PCV20:
20 Common STs (OPA GMRs)



PCV21 PHASE 3 PIVOTAL NI STUDY VS PCV20:
11 Common STs (OPA GMRs)^{2,3}



The PCV21 Phase 3 study shows tighter error bars given larger study size and powering

ST = serotypes. NI = noninferiority; OPA = opsonophagocytic activity; GMR = geometric mean ratio.

(1) 95% CI lower bound >1.0.
(2) Source: package insert Capvaxive.
(3) Common serotypes are those in VAX-31 shared with PCV20 and PCV21 per product labeling. PCV21 is indicated for the prevention of IPD caused by serotypes 15B and 15C but contains only the 15C antigen; however, 15B responses were evaluated.

Consistent with Precedent, VAX-31 Will Be Evaluated Based on Totality of Evidence, Not a Tally of Noninferiority Hits or Misses

WHAT THE FDA HAS CONSIDERED BASED ON TOTALITY OF EVIDENCE:

BREADTH OF SEROTYPE AND DISEASE COVERAGE Incremental serotypes and circulating disease covered vs. comparator	MAGNITUDE OF IMMUNE RESPONSE Robust titers FDA considers protective
CLINICAL RELEVANCE OF ANY MISS Disease burden of affected serotype	OVERALL BENEFIT-RISK Safety, tolerability, public health value

Clear Expectations Ahead of OPUS-1 Reflect Confidence in Delivering Best-in-Class Pneumococcal Vaccine

VAX-31 VS. PCV20

High confidence based on data from Phase 2 head-to-head

+11 incremental serotypes

+31-36% incremental disease coverage

+25% average improvement in GMTs across all 20 STs in Phase 2 trial for VAX-31 compared to PCV20

Base case: 1 expected ST miss (22F)¹

Robust immune responses, exceeding threshold FDA considers protective

Upside case: No ST misses (replicating Ph2 data)

VAX-31 VS. PCV21

Expect strong performance based on triangulation of existing data

+10 additional serotypes

+13-19% incremental disease coverage

Base case: handful of expected ST misses (3, 8, 23B, 31, 35B)¹

Robust immune responses, exceeding threshold FDA considers protective


Upside case: 3-4 ST misses (including ST 3)

OPUS-1 Readout Approaches from a Position of Strength

STRENGTHENED COMPETITIVE SETUP AND SUBSTANTIALLY MORE ST AND DISEASE COVERAGE THAN CURRENT STANDARD-OF-CARE PCVs			
VAX-31 is the only high-valent, next-generation adult PCV in late-stage development	Across the industry, four adult pneumococcal vaccine programs were recently discontinued and/or data have not delivered a compelling clinical profile	The 0.67 noninferiority threshold in OPUS-1 Phase 3 trial has the potential to create a more difficult path for any followers	OPUS-1, OPUS-2, and OPUS-3 are fully enrolled ; OPUS-1 on track for topline data by the end of October 2026¹

OPUS-2 Phase 3 Clinical Trial Evaluating VAX-31 Concomitantly Administered with Seasonal Influenza Vaccine (n=1,390 Dosed)


Descriptive Study Evaluating Safety, Tolerability and Immunogenicity of VAX-31¹ when Administered Either Concomitantly with or One Month Following Administration of a Licensed Seasonal Influenza Vaccine in Healthy Pneumococcal-Naïve² Adults Aged ≥50 Years



OPA = opsonophagocytic activity, IgG = immunoglobulin G, HAI = hemagglutination inhibition, SIV = seasonal influenza vaccine.
(1) VAX-31 High Dose (all serotypes dosed at 3.3mcg, except serotypes 1, 5, and 22F which are dosed at 4.4mcg) selected to advance to Phase 3.
(2) No known prior history of IPD or pneumococcal pneumonia, or receipt of any licensed or investigational pneumococcal vaccine.

OPUS-3 Phase 3 Clinical Trial Evaluating VAX-31 in Healthy Adults Who Have Previously Received a Pneumococcal Vaccine (n=752 Dosed)

Descriptive Study Evaluating Safety, Tolerability and Immunogenicity of a Single Dose Of VAX-31¹ in Healthy U.S. Adults Aged 50 Years and Older with a History of Prior Pneumococcal Vaccination²



OPUS-2 and OPUS-3 Phase 3 Clinical Trial Key Objectives

Descriptive Phase 3 Studies Designed to Demonstrate VAX-31’s Performance in Real-World Adult Use

OPUS-2: PHASE 3 TRIAL EVALUATING VAX-31 CONCOMITANTLY ADMINISTERED WITH SEASONAL INFLUENZA VACCINE	
KEY IMMUNOGENECITY OBJECTIVES	• Primary Objective: Assessing serotype-specific immune responses (OPA GMTs and GMFRs) elicited by VAX-31 across all 31 serotypes and serotype 20B in healthy pneumococcal-naïve adults aged 50 years and older
	• Primary Objective: Comparing strain-specific immune responses (HAI GMTs) elicited by a SIV when co-administered with VAX-31 to those elicited by a SIV alone
	• Secondary Objective: Comparing IgG antibody responses (IgG GMCs) elicited by VAX-31 across all 31 serotypes and serotype 20B when VAX-31 is co-administered with a SIV to those elicited by VAX-31 alone
KEY SAFETY & TOLERABILITY OBJECTIVES	• Participants will be followed for safety through Month 7 after Dose 1, including SAE, NOCI, and MAAE; Day 1 to Day 7, solicited adverse events will be evaluated; Day 1 to Month 1, all unsolicited AEs will be evaluated
OPUS-3: PHASE 3 TRIAL EVALUATING VAX-31 IN HEALTHY ADULTS WHO HAVE PREVIOUSLY RECEIVED A PNEUMOCOCCAL VACCINE	
KEY IMMUNOGENECITY OBJECTIVES	• Primary Objective: Assessing serotype-specific immune responses (OPA GMTs and GMFRs) elicited by VAX-31 across all 31 serotypes and serotype 20B in adults who have previously received PPSV23, PCV20 or other prior licensed pneumococcal vaccines or combinations thereof
	• Secondary Objective: Describing serotype-specific IgG antibody responses (IgG GMCs and GMFRs) elicited by VAX-31 across all 31 serotypes and serotype 20B
KEY SAFETY & TOLERABILITY OBJECTIVES	• Participants will be followed for safety through Month 6 after Dose 1, including SAE, NOCI, and MAAE; Day 1 to Day 7, solicited adverse events will be evaluated; Day 1 to Month 1, all unsolicited AEs will be evaluated

Overview: VAX-31 Adult Phase 1/2 Study Results

Positive VAX-31 Phase 1/2 Adult Data Published in *Lancet Infectious Diseases*

Unprecedented Results Support Potential Best-in-Class PCV With Broadest Serotype and Disease Coverage



Overall study results positive and met objectives



Well tolerated, demonstrating a safety profile similar to PCV20



At all doses studied, VAX-31 demonstrated robust OPA and IgG immune responses for all 31 STs, all three doses advanceable to Phase 3




VAX-31 data further validate the potential of Vaxcyte's carrier-sparing platform to deliver best-in-class PCVs



VAX-31 High Dose selected to advance to Phase 3

VAX-31 Induced Robust Immune Responses for All 20 Common STs

Middle and High Doses Met OPA Response Noninferiority Criteria for All 20 Common STs Compared to PCV20



Low Dose: 8 of 20 STs had a GMR greater than 1.0 and 3 STs achieved statistically higher immune responses


Middle Dose: 13 of 20 STs had a GMR greater than 1.0 and 5 STs achieved statistically higher immune responses

High Dose: 18 of 20 STs had a GMR greater than 1.0 and 7 STs achieved statistically higher immune responses

* Reached statistical significance for superiority.

VAX-31 Induced Robust Immune Responses for All 11 Incremental STs

All Three Doses Met Superiority Criteria for All Incremental STs Compared to PCV20



VAX-31 Full Six-Month Safety Data Similar to PCV20 and Across Cohorts

	VAX-31 Low Dose	VAX-31 Middle Dose	VAX-31 High Dose ¹	PCV20
NUMBER OF SUBJECTS WITH:	255	254	253	253
Unsolicited TEAE, n (%)	42 (16.5)	43 (16.9)	47 (18.6)	42 (16.6)
Related Unsolicited TEAE, n (%)	7 (2.7)	11 (4.3)	17 (6.7)	12 (4.7)
MAAE, n (%)	45 (17.6)	42 (16.5)	35 (13.8)	31 (12.3)
Related MAAE, n (%)	1 (0.4)	4 (1.6)	0	0
NOCI, n (%)	2 (0.8)	6 (2.4)	5 (2.0)	5 (2.0)
Related NOCI, n (%)	1 (0.4)	0	0	0
SAE, n (%)	2 (0.8)	3 (1.2)	5 (2.0)	3 (1.2)
Related SAE, n (%)	0	0	0	0
Death, n (%)	0	0	0	0
Related Death, n (%)	0	0	0	0



PCV Infant Clinical Program

VAXCYTE
protect humankind™



VAX-31 Designed to Expand Protection with Broadest Disease Coverage in Children


Percentage of IPD and Pneumococcal Acute Otitis Media Covered by PCVs in U.S. Children



All estimates assume cross-protection between serotypes 6A and 6C and between 15B and 15C.
(1) CDC 2022-2024 Active Bacterial Core (ABC) Surveillance data; IPD cases with missing serotype data were excluded, non-typeable cases were included in the denominator.
(2) In U.S. children five years of age or under, VAX-31 is estimated to address ~96% of AOM: Grant LR et al., FrontPediatr.2024;12:1383748. Serotype percentages reflect 2017–2021 data (Supplemental Table 1).
(3) VAX-31 includes all serotypes covered by VAX-24, plus an additional 7 serotypes; VAX-24 coverage is depicted in light green and covers 66% of IPD cases in U.S. children <5 years and 62% of AOM cases in U.S. children ≤5 years.

VAX-31 Designed to Deliver Broadest Disease and Serotype Coverage in Infants, Including ~91% of Invasive Pneumococcal Disease (IPD) in U.S. Children¹

VAX-31's UNIQUE 11 STs: Across multiple adult and infant studies, Vaxcyte's PCVs have shown strong immune responses across all incremental STs relative to PCV20. VAX-31, in particular, could significantly increase coverage versus today's standard-of-care.




VAX-31'S UNIQUE STs HAVE POTENTIAL TO PROVIDE 27-47% MORE IPD COVERAGE COMPARED TO CURRENT STANDARD-OF-CARE INFANT PCVs

LEGACY SHARED 20 STs: In the infant study, VAX-24 had higher responses on the highest circulating STs (3 & 19F) and while there were some lower relative responses compared to PCV20, they were restricted to a small subset of shared STs with limited residual disease.

VAX-31 Designed to Deliver Broadest Disease and Serotype Coverage in Infants, Including ~96% of Pneumococcal Acute Otitis Media (AOM) in U.S. Children¹

VAX-31's UNIQUE STs VS STANDARD-OF-CARE INFANT PCVs:

Potential to Provide 35-62% Increase in AOM Coverage Compared to Current Standards-of-Care Infant PCVs



VAX-31'S UNIQUE STs COMPARED TO CURRENT INFANT STANDARD-OF-CARE PCVs

Healthcare Providers Confirm: Broader Coverage Wins in PCV Selection

U.S. pediatric and family medicine providers overwhelmingly favor broader-coverage PCVs and would take action to expand protection for infants.¹

BROAD PROTECTION DRIVES HCP ADOPTION



93%

of HCPs **prefer higher coverage PCVs**, and **80%** agree higher coverage will reduce IPD

PROVIDERS WOULD SWITCH MID-SERIES



76%

would switch infants to broader-coverage PCV even **mid-series** to maximize protection

WILLINGNESS TO PRESCRIBE “CATCH UP”



60%

would prescribe another dose of broader-coverage PCV for already-vaccinated children under 5

OTITIS MEDIA PREVENTION MATTERS



84%


say protection against **acute otitis media** is an important vaccine feature

VAX-31 Infant Clinical Program



Enrollment Completed in VAX-31 Infant Phase 2 Study

3-Stage, Dose-Finding Study Evaluating Safety, Tolerability and Immunogenicity vs PCV20 in 900 Participants



Stage 1 (safety review; completed): The safety and tolerability of VAX-31 was evaluated at three dose levels (Low, Middle and High) and compared to PCV20 in 48 infants in a dose-escalation approach.

Stage 2 (modified and incorporated into Stage 3): Evaluating the safety, tolerability and immunogenicity of VAX-31 at the same three dose levels and compared to PCV20. The study includes a primary immunization series with doses given at two, four and six months of age, followed by a booster dose at 12-15 months of age.

Stage 3 (enrollment completed): The modified study, including the VAX-31 Optimized Dose arm, has completed enrollment in the third and final stage of the study. The Middle and High Dose arms are continuing in Stage 3 as planned. All participants will be evaluated for safety through six months after the booster dose.

Study Safety, Tolerability and Immunogenicity Key Outcome Measures

	DAY 7 AFTER EACH DOSE	1 MONTH POST-DOSE 3	1 MONTH POST-DOSE 4	6 MONTHS POST-DOSE 4
SAFETY AND TOLERABILITY OUTCOME MEASURES	- Solicited local reactions - Solicited systemic events	- Unsolicited adverse events (AE) - Serious adverse events (SAE), new onset of chronic illnesses (NOCI) and medically attended adverse events (MAAE)	SAE, NOCI and MAAE	SAE, NOCI and MAAE
IMMUNOGENICITY OUTCOME MEASURES		% of subjects achieving Immunoglobulin G (IgG) antibody concentration ≥ 0.35 mcg/mL - IgG Geometric Mean Concentration (GMC) - Opsonophagocytic activity (OPA) Geometric Mean Titer (GMT)	- IgG GMC % of subjects achieving IgG antibody concentration ≥ 0.35 mcg/mL % of subjects achieving IgG concentration ≥ 1.0 mcg/mL - OPA GMT - IgG and OPA Geometric Mean Fold Rise (GMFR) from pre-dose 4 to 1-month post-dose 4 % of subjects achieving a 4-fold rise in IgG and OPA from pre-dose 4 to 1-month post-dose 4	

VAX-24 Infant Phase 2 Dose-Finding Study Final Results

Final VAX-24 Phase 2 Infant Study Results and Platform Demonstrate Potential to Achieve Broadest Coverage of Any Infant PCV On-Market



Overall study results positive and met objectives



Well tolerated, demonstrating a safety profile similar to PCV20



VAX-24 elicited substantial IgG, OPA and memory responses and performed particularly well against currently circulating serotypes contained in the vaccine




Substantial, dose-dependent immune responses and little to no evidence of carrier suppression observed



Results consistent with previously reported positive interim results; provide additional evidence validating rationale for exploring higher doses in ongoing VAX-31 infant Phase 2 dose-finding study

VAX-24 Infant Phase 2 Dose-Finding Clinical Study (N=803)


Randomized, Observer-Blind, Active-Controlled, Dose-Finding, Clinical Study to Evaluate Safety, Tolerability and Immunogenicity of VAX-24 vs. Standard-of-Care (PCV20) in 803 Healthy Infants



(*) The 36 subjects from the three VAX-24 cohorts in Stage 1 proceeded to Stage 2 of the study. The 12 subjects who received PCV15 in Stage 1 were given PCV20 in Stage 2 and followed separately; they are not included in the safety or immunogenicity evaluable populations. Two (2) subjects withdrew after being randomized in Stage 2.

Three VAX-24 Doses Evaluated in Infant Phase 2 Dose-Finding Study

Identical to Doses Evaluated in VAX-24 Adult Program



Final 6-Month Safety Data from VAX-24 Phase 2 Study

Safety Results Similar to PCV20 and Across Cohorts


	VAX-24 Low Dose	VAX-24 Mid Dose	VAX-24 Mixed Dose	PCV20
NUMBER OF SUBJECTS	195	186	191	185
Unsolicited TEAE, n (%)	167 (85.6)	161 (86.6)	163 (85.3)	169 (91.4)
Related Unsolicited TEAE, n (%)	6 (3.1)	13 (7.0)	13 (6.8)	6 (3.2)
MAAE, n (%)	172 (88.2)	155 (83.3)	167 (87.4)	161 (87.0)
Related MAAE, n (%)	3 (1.5)	3 (1.6)	3 (1.6)	1 (0.5)
NOCI, n (%)	12 (6.2)	12 (6.5)	15 (7.9)	10 (5.4)
Related NOCI, n (%)	0	1 (0.5) ¹	0	0
SAE, n (%)	10 (5.1)	7 (3.8)	11 (5.8)	11 (5.9)
Related SAE, n (%)	0	0	0	0
Death, n (%)	0	0	0	1 (0.5) ²
Related Death, n (%)	0	0	0	0

Final Post-Dose 3 (PD3) IgG and OPA Immunogenicity Data Results

VAX-24 PD3 Seroconversion Rates Compared to PCV20

Met Precedent Phase 2 Noninferiority Criteria for 20 of 24 STs at Low and Mid Doses and 19 of 24 STs at Mixed Dose

VAX-24 vs. PCV20: Difference in % of Subjects Meeting Predefined IgG Levels²



NI = noninferiority; ST = serotype; IgG = immunoglobulin G.

(1) % of IPD caused in individuals <5 yrs of age in the U.S. in 2022-2024 based on ABC surveillance data.


(2) % of subjects meeting ≥ 0.35 mcg/mL for unique STs were calculated compared to ST 6B, which is the ST in PCV20 with the lowest seroconversion rate Post-Dose 3 (excluding ST 3 or lower responding STs).

(3) Serotypes 6A/6C and 15B/15C are closely related subtypes for which cross-protection is assumed.

(4) The serogroup 20 antigen contained in VAX-24 and VAX-31, formerly known as a 20B variant, has been officially reclassified as 20C. For additional details on serogroup 20, please see footnote 2 on slide 15.

VAX-24 PD3 OPA GMT Immune Responses


Demonstrated Robust OPA Titers, Generally Consistent with IgG Responses



OPA = opsonophagocytic activity; GMT = geometric mean titer; IgG = immunoglobulin G.


Final Post-Dose 4 (PD4) IgG and OPA Immunogenicity Data Results

VAX-24 Demonstrated High Overall Seroconversion Rates Across All Doses PD4



VAX-24 PD4 IgG GMRs Compared to PCV20

Met Target Ph2 Noninferiority Criteria for Point Estimate of >0.6 on 19 of 24 STs at Mixed Dose and 18 of 24 STs at Mid Dose




GMR = geometric mean ratio; IgG = immunoglobulin G; ST = serotype.



(1) % of IPD caused in individuals <5 yrs of age in the U.S. in 2022-2024 based on ABC surveillance data.
(2) GMRs for unique STs were calculated compared to ST 12F, which is the ST in PCV20 with the lowest GMC Post-Dose 3 (excluding ST 3 or lower responding STs).
(3) Serotypes 6A/6C and 15B/15C are closely related subtypes for which cross-protection is assumed.
(4) The serogroup 20 antigen contained in VAX-24 and VAX-31, formerly known as a 20B variant, has been officially reclassified as 20C. For additional details on serogroup 20, please see footnote 2 on slide 15.


VAX-24 PD4 OPA GMT Immune Responses

Demonstrated Robust OPA Titers, Generally Consistent with IgG Responses



OPA = opsonophagocytic activity; GMT = geometric mean titer; IgG = immunoglobulin G.

VAX-24 Demonstrated Robust Memory Responses Pre- vs Post-Dose 4 IgG GMCs




GMC = geometric mean concentration; IgG = immunoglobulin G.

Expanded Analysis of Concomitant Flu Vaccination & Dose-Dependent Immune Responses

VAX-24 PD4 IgG GMRs Compared to PCV20 Including Subjects Who Received Flu Vaccination

Consistently Improved Immunogenicity Responses Evidenced in Mid Dose

IgG Geometric Mean Ratios for VAX-24 vs. PCV20




GMR = geometric mean ratio; IgG = immunoglobulin G.
The IEP4 includes eligible subjects who received the same vaccine across all 4 doses, with valid PD4 IgG or OPA assay results based on blood sample collected within protocol-defined window, and without protocol deviations that may interfere with PD4 immune response.
The IEP4 + Flu population includes all eligible subjects from the IEP4 population and an additional 12 participants who followed protocol and received a flu vaccine.
This is not a complete study evaluating the concomitant administration of VAX-24 with other vaccines. The findings presented are limited in scope and are not necessarily indicative of how VAX-24 would perform in studies designed to assess concomitant administration.


Dose Response Evidenced PD4 Across Most Serotypes

Supports Dosing Strategy for Ongoing VAX-31 Infant Phase 2 Study

DOSE-DEPENDENT IMMUNOGENICITY OBSERVED ACROSS DOSE RANGE¹



LITTLE TO NO CARRIER SUPPRESSION EVIDENCED BY SIMILAR PERFORMANCE ACROSS DIFFERENT LEVELS OF PROTEIN CARRIER CONTENT



GMR = geometric mean ratio; GMC = geometric mean concentration; IgG = immunoglobulin G.

Group A Strep Opportunity & VAX-A1 Clinical Program



Group A Strep: Among the World's Most Significant Bacterial Pathogens

Streptococcus pyogenes, or **Group A Strep**, is a pathogen that causes a wide array of disease from common acute infections to chronic conditions, resulting in a **significant public health burden**

GROUP A STREP IS A GRAM (+) BACTERIUM THAT IS RESPONSIBLE FOR...



Acute infections: pharyngitis, also known as strep throat, and superficial skin infections (e.g., impetigo)



Invasive and toxin-mediated disease: necrotizing fasciitis, sepsis, meningitis, pneumonia, cellulitis, scarlet fever and streptococcal toxic shock syndrome



Immune-mediated conditions: acute rheumatic fever, rheumatic heart disease and post-streptococcal glomerulonephritis (a form of kidney inflammation)

PUBLIC HEALTH BURDEN



Group A Strep is responsible for ~800M cases of illness and more than 600K deaths annually worldwide¹, yet no approved vaccine for Group A Strep exists




The annual U.S. economic burden of Group A Strep is estimated to exceed \$6B, with hospitalizations due to invasive disease accounting for ~\$2B annually²

Group A Strep Infection Rates Have Increased Substantially

HIGH RATES OF INVASIVE GROUP A STREP POST-COVID PANDEMIC IN THE U.S.


Annual Rates of Invasive Group A Strep Infections in the U.S.¹



Currently available CDC data demonstrates pre- and post-COVID-19 pandemic Invasive Group A Strep rates, with the most recent 2024 data indicating early stabilization³

SIGNIFICANT INCREASE IN PHARYNGITIS RATES POST-COVID PANDEMIC IN THE U.S.²

Percentage of Encounters for Pharyngitis by Age in the U.S.²



Growing Threat of Antibiotic Resistance Against Group A Strep

Group A Strep Drives Significant Antibiotic Use, Especially Among Children,
Contributing to Rising Antimicrobial Resistance

RISING ANTIBIOTIC RESISTANCE



Antibiotic resistance to Group A Strep has increased over the past decade¹, leading the CDC to categorize the disease as a concerning threat²



~1 in 3 invasive Group A Strep infections are now caused by bacteria that are resistant to erythromycin and clindamycin³

FALLING TREATMENT CAPACITY



Group A Strep drives an estimated **18.5M antibiotic courses annually worldwide**⁴, yet antimicrobial development in biopharma industry has **dropped 35% in five years**⁵



Penicillin remains the preferred antibiotic treatment for Group A Strep but **mutations in penicillin binding protein are beginning to manifest globally, showing early signs of reduced susceptibility**⁶

(1) <https://jamanetwork.com/journals/jama/fullarticle/2832277>.

(2) <https://www.cdc.gov/antimicrobial-resistance/media/pdfs/qas-508.pdf>.

(3) <https://www.cdc.gov/group-a-strep/php/surveillance/index.html>.

(4) <https://pmc.ncbi.nlm.nih.gov/articles/PMC10663680/>.

(5) Based on an assessment of seven large research-based pharmaceutical companies; <https://accessmedicinefoundation.org/medialibrary/antimicrobial-resistance-benchmark-2026-1773667785.pdf>.

(6) <https://pubmed.ncbi.nlm.nih.gov/31996443/>.

VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Strep

VAX-A1 IS DESIGNED TO:

Provide broad, strain-independent protection via a disease-specific protein carrier combined with a universal, species-defining polysaccharide (PS) to enable protection across a wide range of Group A Strep subtypes

Leverage cell-free protein synthesis platform to enable site-specific conjugation of the PS to disease-specific carrier to maintain exposure of its mapped T- and B-cell epitopes

Disarm key pathogen defense mechanisms via three conserved anti-virulence antigens that engender immune responses to the pathogen’s virulence factors themselves to enhance pathogen clearance and reduce disease severity

Address a large, underserved global opportunity, with the total Group A Strep vaccine market estimated at **~\$3-4B annually**¹




VAX-A1: Conjugate Vaccine with Multiple Modes of Action

Protein-Polysaccharide Conjugate

SpyAD & Universal Polysaccharide (GAC^{PR})¹

SpyAD, a surface-expressed highly-conserved antigen needed for adhesion and division to host cell membranes, site-selectively conjugated to the Universal Polysaccharide (GAC^{PR}) to generate a novel conjugate vaccine




GAC^{PR} is comprised of a Polyrhamnose (PR) backbone, which has been designed to remove potentially cross-reactive epitopes associated with autoimmune complications

Protein Components

Streptolysin O (SLO)

A pore-forming cytotoxin; included in VAX-A1 in detoxified form to neutralize and clear a key anti-phagocytic mechanism of bacterial defense




C5a Peptidase (ScpA)

Surface-expressed antigen that cleaves human C5a complement protein, which delays recruitment of phagocytes to the site of infection and alters clearance and trafficking of Group A Strep



Phase 1 Two-Stage, Dose-Escalation Study Evaluating VAX-A1 in Adults: Currently Enrolling 18-40 yr olds (n~80)



Key Study Objectives: the primary objective is to assess safety and tolerability, along with the secondary objective to evaluate initial immunogenicity data

Study Site: the study is being conducted at an investigative site in Australia, where Group A Strep has been especially problematic and where there are experienced investigator networks with expertise in Group A Strep

(1) DSMB = Data Safety Monitoring Board.

(2) Dose escalation for each cohort is based on a review of blinded safety and tolerability data by the Company's Internal Safety Team prior to proceeding with enrolling the next cohort.

(3) Following DSMB review, Stage 1 participants will receive Dose 2 at Month 2 and then follow the same protocol as Stage 2 through Month 8.

VAX-A1 Phase 1 Study Key Objectives


Primarily Designed to Assess Safety and Tolerability, with Secondary Objective to Assess Immune Responses

	PRIOR TO EACH DOSE	DAY 7 (AFTER EACH DOSE)	1 MONTH (AFTER EACH DOSE)	8 MONTHS (AFTER DOSE 1)	ENTIRE DURATION OF STUDY
PRIMARY OUTCOME MEASURES: SAFETY AND TOLERABILITY		- Solicited local reactions - Solicited systemic adverse events (AE) - AE	Unsolicited AE	- Medically attended adverse events (MAAE) - New onset chronic illness (NOCI) - Serious adverse events (SAE) - AE of special interest¹	- MAAE - NOCI - SAE - AE of special interest
SECONDARY OUTCOME MEASURES: ANTIGEN-SPECIFIC IMMUNE RESPONSES	For each VAX-A1 antigen ² : - Serum IgG geometric mean titer (GMT) - Serum IgG geometric mean fold rise (GMFR) from baseline - Percentage of participants with serum Immunoglobulin G (IgG) ≥ Lower Limit of Quantification (LLOQ) of the assay	Standard safety laboratory parameters (hematology, coagulation, and clinical chemistry median values and median change from baseline)	For each VAX-A1 antigen: - Serum IgG GMT - Serum IgG GMFR from baseline - Percentage of participants achieving serum IgG ≥2-fold increase from baseline - Percentage of participants with serum IgG ≥ LLOQ of the assay	For each VAX-A1 antigen: - Serum IgG GMT - Serum IgG GMFR from baseline - Percentage of participants achieving serum IgG ≥2-fold increase from baseline - Percentage of participants with serum IgG ≥ LLOQ of the assay	

VAX-A1 Preclinical Data Published in *Infectious Microbes & Diseases*¹ Supported Advancement into the Clinic

In This Study, VAX-A1 Demonstrated Protective Immunity Against Group A Strep in Preclinical Systemic and Skin Infection Models

OBJECTIVE	The study examined the efficacy of a novel polysaccharide protein conjugate for a vaccine covering all serotypes of Group A Strep
RESULTS	- The vaccine elicited antibodies that were protective in systemic and soft tissue mouse models of infection - In preclinical testing, mice immunized with VAX-A1 yielded 100% survival against lethal challenge - Broad-based cross-reactivity with multiple M protein serotypes of Group A Strep was observed - No evidence of cross-reactivity to human heart or brain antigens



Shigella: VAX-GI Preclinical Program



VAX-GI: Shigella Vaccine Program

Novel Shigella Vaccine to Prevent Widespread Global Morbidity & Mortality, Particularly in Children

UNMET NEED	- Shigella is a bacterial illness with no available preventative treatment - Estimated to cause 80-165 million cases of disease and 600,000 deaths annually, and most cases and deaths are among children¹ - With the aim of reducing morbidity and mortality due to the disease, the World Health Organization lists Shigella vaccine development as a priority goal²																																																							
VAX-GI: NOVEL SHIGELLA VACCINE	- Development collaboration with the University of Maryland, Baltimore; supported with funding by two National Institutes of Health grants with total potential funding of up to \$5.1M - Plan to pursue conjugate and protein-only approaches simultaneously - Conjugate approach: IpaB-LPS/IpaH/VirG; Protein-only approach: IpaB/IpaH/VirG																																																							
PROGRAM STATUS	Decision on final candidate to be determined by a human challenge study conducted at the University of Maryland, Baltimore																																																							
MOA & KEY DATA	- Targeting IpaB inhibits assembly of T3SS and toxin delivery to immune cells - Opsonophagocytosis and killing of bacteria VAX-GI: Conjugate Approach <table><caption>VAX-GI: Conjugate Approach - Percent Survival Data</caption><tr><th>Days After Challenge</th><th>IpaBmut1-OPS</th><th>IpaB</th><th>CRM-OPS</th><th>Alum alone</th></tr><tr><td>4</td><td>~100</td><td>~60</td><td>~40</td><td>~40</td></tr><tr><td>6</td><td>~100</td><td>~60</td><td>~40</td><td>~40</td></tr><tr><td>8</td><td>~100</td><td>~60</td><td>~40</td><td>~40</td></tr></table> VAX-GI: Protein Only Approach <table><caption>VAX-GI: Protein Only Approach - % Survival Data</caption><tr><th>Days after challenge</th><th>IpaB 5µg</th><th>IpaB 10µg</th><th>IpaB 20µg</th><th>Control</th></tr><tr><td>4</td><td>~100</td><td>~100</td><td>~100</td><td>~100</td></tr><tr><td>6</td><td>~60</td><td>~60</td><td>~100</td><td>~15</td></tr><tr><td>8</td><td>~60</td><td>~60</td><td>~100</td><td>~15</td></tr><tr><td>10</td><td>~60</td><td>~60</td><td>~100</td><td>~15</td></tr><tr><td>12</td><td>~60</td><td>~60</td><td>~100</td><td>~15</td></tr><tr><td>14</td><td>~60</td><td>~60</td><td>~100</td><td>~15</td></tr></table> Diagram A: Schematic of the Shigella T3SS (Type III Secretion System) structure. The diagram shows the needle tip complex (IpaD, IpaB) crossing the outer membrane (OM) and inner membrane (IM) rings. The needle is composed of MxiH, MxiA, PcrD, and FliH. The needle is surrounded by a needle periplasmic rod (MxiI) and a periplasmic region. The needle is anchored in the inner membrane by a socket. The inner membrane ring is composed of MxiA/PcrD/FliH. The needle is surrounded by an export apparatus (IMEA) and an ATPase complex (CEA). The diagram also shows the needle tip complex (IpaD, IpaB) and the needle periplasmic rod (MxiI) crossing the outer membrane (OM) and inner membrane (IM) rings. The needle is anchored in the inner membrane by a socket. The inner membrane ring is composed of MxiA/PcrD/FliH. The needle is surrounded by an export apparatus (IMEA) and an ATPase complex (CEA).	Days After Challenge	IpaBmut1-OPS	IpaB	CRM-OPS	Alum alone	4	~100	~60	~40	~40	6	~100	~60	~40	~40	8	~100	~60	~40	~40	Days after challenge	IpaB 5µg	IpaB 10µg	IpaB 20µg	Control	4	~100	~100	~100	~100	6	~60	~60	~100	~15	8	~60	~60	~100	~15	10	~60	~60	~100	~15	12	~60	~60	~100	~15	14	~60	~60	~100	~15
Days After Challenge	IpaBmut1-OPS	IpaB	CRM-OPS	Alum alone																																																				
4	~100	~60	~40	~40																																																				
6	~100	~60	~40	~40																																																				
8	~100	~60	~40	~40																																																				
Days after challenge	IpaB 5µg	IpaB 10µg	IpaB 20µg	Control																																																				
4	~100	~100	~100	~100																																																				
6	~60	~60	~100	~15																																																				
8	~60	~60	~100	~15																																																				
10	~60	~60	~100	~15																																																				
12	~60	~60	~100	~15																																																				
14	~60	~60	~100	~15																																																				

Key Corporate Highlights



Large Market Opportunity for Broadest-Spectrum PCV

Cell-Free Protein Synthesis Enabled Pipeline


Aligned Critical Commercial Manufacturing
and Supply Chain Resources

Robust Pipeline with Multiple Novel Vaccines

Appendix

Spectrum of Coverage Drives Adoption in PCV Segment

VAX-31 Designed to Increase Coverage to ~95% of IPD Circulating in U.S. Adults



(1) The serogroup 20 antigen contained in VAX-24 and VAX-31, formerly known as a 20B variant, has been officially reclassified as 20C. For additional details on serogroup 20, please see footnote 2 on slide 15.

(2) 15C coverage due to cross-reaction against 15B. 6C coverage due to cross-protection by 6A.

(3) % of IPD caused in individuals ≥50 yrs of age in the U.S. in 2022-2024 based on ABC surveillance data.

Pediatric Segment Represents Majority of ~\$8B Pneumococcal Vaccine Market


VAX-31: 31-valent PCV with potential to increase serotype coverage and address ~96% of acute otitis media.¹



(4) % of IPD caused in individuals <5 yrs of age in the U.S. in 2022-2024 based on ABC surveillance data.

On-Market PCVs Elicit Antibodies for Disease Protection With Range of Results


Serotype 3 (ST3) Conjugate Elicits Weakest Antibody Response Among All Conjugates



ST3 REMAINS AN OUTLIER AS CIRCULATION HAS NOT BEEN EFFECTIVELY CONTROLLED BY VACCINATION

KEY FACTORS DETERMINE WHY ST3 REQUIRES HIGHER LEVEL OF PROTECTIVE ANTIBODY

- **Thick Polysaccharide Capsule:** serotype 3 forms a robust physical barrier that impairs opsonization and phagocytosis, requiring higher antibody levels for effective coating
- **Capsule Shedding & Antibody Neutralization:** serotype 3 releases free polysaccharides that bind and neutralize antibodies before they reach the bacterial surface



- **Reduced Opsonophagocytic Efficiency:** mucoid capsule limits complement (C3b) deposition and phagocyte recognition, making ST3 less susceptible to immune clearance



Contact:

Jeff Macdonald, Executive Director, Investor Relations
investors@vaxcyte.com

